Browsing ICR Divisions by author "Bridgeman, Victoria"
Now showing items 1-3 of 3
-
Preclinical Evidence That Trametinib Enhances the Response to Antiangiogenic Tyrosine Kinase Inhibitors in Renal Cell Carcinoma.
Bridgeman, VL; Wan, E; Foo, S; Nathan, MR; Welti, JC; et al. (AMER ASSOC CANCER RESEARCH, 2016-01-01)Sunitinib and pazopanib are antiangiogenic tyrosine kinase inhibitors (TKI) used to treat metastatic renal cell carcinoma (RCC). However, the ability of these drugs to extend progression-free and overall survival in this ... -
Vessel co-option is common in human lung metastases and mediates resistance to anti-angiogenic therapy in preclinical lung metastasis models.
Bridgeman, VL; Vermeulen, PB; Foo, S; Bilecz, A; Daley, F; et al. (WILEY, 2017-02-01)Anti-angiogenic therapies have shown limited efficacy in the clinical management of metastatic disease, including lung metastases. Moreover, the mechanisms via which tumours resist anti-angiogenic therapies are poorly ... -
Vessel co-option mediates resistance to anti-angiogenic therapy in liver metastases.
Frentzas, S; Simoneau, E; Bridgeman, VL; Vermeulen, PB; Foo, S; et al. (NATURE PUBLISHING GROUP, 2016-11-01)The efficacy of angiogenesis inhibitors in cancer is limited by resistance mechanisms that are poorly understood. Notably, instead of through the induction of angiogenesis, tumor vascularization can occur through the ...